Lumenis Ltd. is a global medical device company that develops, manufactures, and sells energy-based medical solutions for aesthetic, surgical, and ophthalmic applications. The company was founded in 1991 and is headquartered in Yokneam, Israel.
Lumenis offers a range of products, including laser and intense pulsed light (IPL) systems for aesthetic procedures such as hair removal, skin rejuvenation, and treatment of vascular and pigmented lesions; surgical lasers for ophthalmology, ear, nose, and throat procedures, and other surgical applications; and ophthalmic lasers for the treatment of cataracts, glaucoma, and other conditions. The company also offers a variety of accessories and consumables for its products.
Lumenis has a global presence with offices in more than 100 countries and over 1,200 employees worldwide. The company operates in three segments: Surgical, Aesthetic, and Ophthalmic. The Surgical segment includes products for minimally invasive surgery, such as laser and fiber-optic devices. The Aesthetic segment includes products for non-invasive cosmetic procedures, such as hair removal and skin rejuvenation. The Ophthalmic segment includes products for the treatment of eye conditions, such as cataracts and glaucoma.
Lumenis has a strong focus on research and development, with a significant portion of its revenues invested in developing new technologies and expanding its product portfolio. The company has a number of patents and pending patent applications related to its products and technologies.
In 2019, Lumenis was acquired by Baring Private Equity Asia, a private equity firm based in Hong Kong, for approximately $1.1 billion.
|
